SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in <i>KRAS</i> G12C-mutant advanced NSCLC

Nishio, M.; Negrao, M. V.; Arbour, K. C.; Burns, T. F.; Cappuzzo, F.; Dingemans, A. M. C.; Girard, N.; Gronberg, B. H.; Hochmair, M.; Leal, T.; Lindsay, Colin R; Lu, S.; Paz-Ares, L. G.; Reck, M.; Sabari, J. K.; Spira, A. I.; William, W. N., Jr.; Chen, A.; Grul, C. M. V.; Peters, S.

Affiliation

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom

Issue Date

2024

Metadata

Show full item record

Abstract

Neuroendocrine neoplasms of different origins, parathyroid carcinoma and intrathyroid thymic neoplasms are included.

Citation

Nishio M, Negrao MV, Arbour KC, Burns TF, Cappuzzo F, Dingemans AMC, et al. SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in <i>KRAS</i> G12C-mutant advanced NSCLC. JOURNAL OF CLINICAL ONCOLOGY. 2024 AUG 10;42(23_SUPPL):TPS218-TPS. PubMed PMID: WOS:001346520000008. English.

Journal

Journal of Clinical Oncology

URI

http://hdl.handle.net/10541/627406

Type

Meetings and Proceedings

Language

Collections

All Christie Publications